No Trials Currently Available

IRB# 16893 A Phase I/II Open Label Multi-Center Study of Immune Checkpoint Therapy with Nivolumab for Patients with Locally Advanced Esophageal Squamous Cell Carcinoma

IRB# 18147 A Phase 3, Double-blind, Randomized Study of BGB-290 versus Placebo as Maintenance Therapy in Patients with Inoperable Locally Advanced or Metastatic Gastric Cancer that Responded to Platinum-based First-line Chemotherapy

IRB# 18340 A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of IMAB362 Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-line Treatment of Subjects with Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma ISN/Protocol 8951-CL-0301

IRB# 18147 A Phase 3, Double-blind, Randomized Study of BGB-290 versus Placebo as Maintenance Therapy in Patients with Inoperable Locally Advanced or Metastatic Gastric Cancer that Responded to Platinum-based First-line Chemotherapy

IRB# 16058 A Randomized, Multi-center, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer (CheckMate 577: CHECKpoint pathway and nivolumab clinical Trial Evaluation 577)

IRB# 12071 A Pilot Study Using a Novel Imaging of Lymph Nodes in Patients with Locally Advanced Esophageal Cancer Using Ferumoxytol Enhanced MRI

Key

- Open for Enrollment
- In Development
- Enrollment on Hold

http://www.ohsu.edu/research/rda/so/knight.php